See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
In vitro activity of cefiderocol against Gram-negative bacteria isolated from burn patients
In vitro activity of cefiderocol against Gram-negative bacteria isolated from burn patients
In vitro activity of cefiderocol against carbapenem-nonsusceptible Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in United States hospitals (2020–2024)
In vitro activity of cefiderocol against carbapenem-nonsusceptible Acinetobacter baumannii-calcoaceticus complex, including molecularly characterized clinical isolates, causing infections in United States hospitals (2020–2024)
In vitro activity of cefiderocol against clinical strains collected from China in 2023
In vitro activity of cefiderocol against clinical strains collected from China in 2023
In vitro activity of cefiderocol against resistant subsets of Pseudomonas aeruginosa collected from United States hospitals during 2020–2024
In vitro activity of cefiderocol against resistant subsets of Pseudomonas aeruginosa collected from United States hospitals during 2020–2024
In vitro activity of cefiderocol and comparator agents against global Enterobacterales isolates from hospitalized patients with pneumonia collected as part of the SENTRY Surveillance Program (2020-2022)
In vitro activity of cefiderocol and comparator agents against global Enterobacterales isolates from hospitalized patients with pneumonia collected as part of the SENTRY Surveillance Program (2020-2022)
In vitro activity of cefiderocol and comparator agents against non-fermentative Gram-negative bacilli Isolated from patients hospitalized with pneumonia as part of the SENTRY Global Surveillance Program (2020-2022)
In vitro activity of cefiderocol and comparator agents against non-fermentative Gram-negative bacilli Isolated from patients hospitalized with pneumonia as part of the SENTRY Global Surveillance Program (2020-2022)
You Are Viewing Congress Locations
ASCP 2025
NACFC 2025
IDWeek 2025
AVG and IMRP 2025
ASM Microbe 2025
ESCMID 2025
CROI 2025
SCCM 2025
IDWeek 2024
NACFC 2024
IAS 2024
ESCMID 2024
